VI-TWEL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 36m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VI-TWEL is a small molecule injectable medication approved by Bayer in 1949. The generic name and mechanism of action are unknown, limiting public knowledge of its therapeutic target and clinical application.
LOE Approaching
LOE-approaching status suggests potential team downsizing or commercial focus shift away from growth initiatives toward managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VI-TWEL shows zero linked job openings, reflecting its LOE-approaching status and reduced commercial investment. Career opportunities are limited; professionals should evaluate roles as portfolio diversification or consider transition to growth-stage products.
Brand ManagerMarket Access Manager
Worked on VI-TWEL at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.